News

Diethylcarbamazine, an Anti-parasitic Therapy, Prevents PH in Mice, Brazilian Study Finds

Diethylcarbamazine, a compound used to fight a tropical parasitic disease, might effectively treat pulmonary hypertension (PH), a Brazilian research team concluded after observing the drug’s effect on mice. Their study, “Diethylcarbamazine: A potential treatment drug for pulmonary hypertension?” appeared in the journal Toxicology and Applied Pharmacology. It found that diethylcarbamazine affected disease processes…

Estrogen Reversed PH in Rat Study, Offering Clues to Disease Mechanisms

The female sex hormone estrogen may prevent disease progression of pulmonary hypertension — at least if results in rats can be translated to human patients. Researchers at the University of California, Los Angeles (UCLA) showed that estrogen reversed progression from pulmonary hypertension (PH) to right heart failure, and restored lung…

Adempas May Benefit PAH Patients Who Fail to Respond to PDE5 Inhibitors, Trial Indicates

Bayer’s Adempas (riociguat) can improve the lung and heart functioning of pulmonary hypertension patients who fail to respond to phosphodiesterase-5 inhibitors (PDE5i), a Phase 3 clinical trial suggests. The RESPITE trial also showed that Adempas can improve biomarkers of pulmonary arterial hypertension, or PAH. Researchers published the study in the European…

New Model of Intensive Care Breathing Specialists Working with Heart Doctors Is Promising, Study Reports

Doctors who are intensive care respiratory specialists help seriously ill heart patients with breathing difficulties achieve better outcomes, a University of Maryland School of Medicine study reports. Researchers said the new model of having these specialists work with cardiac specialists also lowers patients’ costs. One reason the model works is that…

Pulmonary Hypertension Survival Rates Vary with Cause of Disease, German Study Finds

Information from a pulmonary hypertension registry at Germany’s University Hospital Giessen indicates that patient survival rates vary with the cause of their disease. Researchers published the results in The Journal of Heart and Lung Transplantation. The study was titled “The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups.” A…

Vascular BioSciences Wins Grant to Study Peptide For Pulmonary Hypertension

Vascular BioSciences (VBS) received a Fast-Track STTR grant of up to $2.3 million to begin a Phase I/II study that will examine CARSKNKDC (CAR) peptide’s efficacy for pulmonary hypertension (PH). The study, titled “Cyclic CAR peptide: a targeted therapy for pulmonary hypertension,” will be conducted in collaboration with Brigham and Women’s Hospital,…

Tracleer Becomes First FDA-approved Therapy in U.S. for Children with Pulmonary Hypertension

Tracleer (bosentan) has become the first therapy to obtain U.S. regulatory approval for treating pulmonary hypertension in children. The Food and Drug Administration authorized it for children aged 3 and older who have idiopathic or congenital pulmonary arterial hypertension (PAH). Actelion Pharmaceuticals, the company that holds the marketing license for…

FDA Declines SteadyMed’s New Drug Application for Trevyent, Delivered via PatchPump, to Treat PAH

The U.S. Food and Drug Administration (FDA) has declined SteadyMed Therapeutics‘ new drug application (NDA) for its Trevyent (treprostinil injection) therapy to treat pulmonary arterial hypertension (PAH). SteadyMed, with offices in San Ramon, California, and in Israel, had submitted its NDA in July 2017. But the application was denied on Aug. 31…